The Content and Distribution of Troponin I, Troponin T, Myoglobin, and alpha-hydroxybutyric Acid Dehydrogenase in the Human Heart
|
|
- Tyrone Black
- 5 years ago
- Views:
Transcription
1 Clinical Chemistry / TROPONINS I AND T, MYOGLOBIN, AND HBD IN THE HUMAN HEART The Content and Distribution of Troponin I, Troponin T, Myoglobin, and alpha-hydroxybutyric Acid Dehydrogenase in the Human Heart Joost C.J.M. Swaanenburg, PhD, 1 Petra J. Visser-VanBrummen, 1 Mike J.L. DeJongste, MD, PhD, 2 and Anton T.H.M. Tiebosch, MD, PhD 1 Key Words: Troponin I; Troponin T; HBD; alpha-hydroxybutyric acid dehydrogenase; Myoglobin; Myocardial tissue content Abstract We studied the content and distribution of heartspecific markers troponin I and troponin T in relation to conventional non heart specific myoglobin and alphahydroxybutyric acid dehydrogenase (HBD) in the hearts of 34 patients who died of various causes. Tissue was obtained from the right and left ventricles, the interventricular septum, and the right and left atria. We found significant differences in the contents expressed per gram wet weight tissue in the right and left ventricles for troponin I (by 1 of the 2 methods used), troponin T, myoglobin, and HBD and no differences per gram of protein. The biochemical contents per gram wet weight tissue and per gram protein were significantly lower in the right and left atria for all studied markers compared with the right and left ventricles. No significant differences were found in biochemical contents between the right and left atria. These findings imply that estimation of myocardial damage through cardiac markers levels in serum depends on the site of injury (atrium or ventricle). Comparison of myocardial injury among individuals using marker levels in serum is not reliable because of the varied ranges of markers in tissue contents. For several years, the level of cardiac markers in blood after an acute myocardial infarction (AMI) has been used to estimate the extent of myocardial tissue damage. 1 Its relevance is indicated by the fact that the prognosis after an AMI is related to the amount of myocardial tissue loss. 2 A frequently used conventional biochemical marker for this purpose is alpha-hydroxybutyric acid dehydrogenase (HBD), 3 a marker analogous to lactate dehydrogenase isoenzyme-1. However, this marker is non heart specific, since the level also is elevated after hemolysis. Another marker that can be used is myoglobin. After an AMI, the increase in the serum concentration of myoglobin is more rapid than the increase of HBD. In addition, the myoglobin concentration normalizes faster. Both markers are non heart specific, since myoglobin and HBD are also components of skeletal muscle tissue. Moreover, because myoglobin is cleared through the kidneys and, thus, depends on the renal function of the patient, the increased serum concentration after an AMI is more difficult to interpret than increased HBD activity. More specific biochemical markers for myocardial tissue damage have been reported, including the cardiac troponins. 4,5 The troponins are components related to the actin-myosin complexes of the thin filaments of striated muscle. These complexes are involved in muscle contraction and relaxation. Three forms of troponin have been described: troponin I, troponin C, and troponin T. Each troponin has its own function. Troponin C binds calcium, which activates muscle contraction. Troponin I inhibits the adenosinetriphosphatase activity of the actin-myosin complex, resulting in muscle relaxation. Troponin T binds the troponin I troponin C complex to tropomyosin. In contrast with troponin C, the amino acid sequences of troponin I and troponin T in skeletal muscle differ from those in myocardial muscle. To separate them immunologically, 77 Am J Clin Pathol 21;115: American Society of Clinical Pathologists
2 Clinical Chemistry / ORIGINAL ARTICLE specific antibodies directed against the cardiac troponins I and T were developed. These antibodies form the basis of the techniques for measuring concentrations of cardiac troponins I and T in serum. Because the amino acid composition of troponin C in skeletal muscle equals that in myocardial muscle, no cardiac troponin C method can be developed to specifically measure myocardial troponin C. To relate the extent of myocardial tissue loss to increased cardiac troponin concentrations in serum, the troponins should be distributed homogeneously in the myocardium and should have similar myocardial contents. 6 So far, a limited number of studies have been reported about the contents of cardiac markers in the heart However, these studies included a limited number of patients, studied hearts of nonhuman origin, focused on troponin I or T, analyzed only the contents of the ventricles, or expressed the contents per gram wet weight tissue or per gram of protein. Our aim was to study the distribution and content (expressed per gram wet weight tissue and per gram of protein) of cardiac troponin I (measured by 2 methods) and cardiac troponin T in the human myocardium in relation to the distribution and the content of the more conventional markers myoglobin and HBD. Materials and Methods Postmortem tissue was obtained from 34 patients at 7 sites in the heart and as negative control from the psoas muscle. Care was taken that all tissue samples were free of scars and necrosis. The samples were taken from the right ventricle (RV); the left ventricle (LV); the posterior, lateral, and anterior walls of the LV; the interventricular septum of the LV; the right atrium (RA); and the left atrium (LA). Immediately after harvesting, samples were weighed and frozen in liquid nitrogen. Subsequently, they were destructed in liquefied nitrogen using the Micro-dismembrator U (Braun Biotech International, Salm and Kipp, Breukelen, the Netherlands) at 2, rpm for 1 minute. After completing the procedure, 5 ml of modified phosphate-buffered saline (ph 7.) was added. The solutions were frozen and stored at 2 C. Subsequently, analysis was performed of the biochemical markers troponin I, troponin T, myoglobin, and HBD, and the protein concentrations were determined. Troponin I was measured using 2 analyzers. One analyzer was the AxSYM (Abbott Diagnostic Division, Hoofddorp, the Netherlands). 13 Instructions of the manufacturer were followed. The coefficients of variation (CVs) at 3 different levels were determined using control serum samples. The CVs were 6.8%, 5.2%, and 5.8%, respectively, for the levels 2.9, 7.6, and 29. ng/ml (2.9, 7.6, and 29. µg/l). The second analyzer was the Access (Beckman, Mijdrecht, the Netherlands) according to the instructions of the manufacturer. 14 The CVs for this assay were 8.9%, 8.2%, and 7.4%, respectively, for the levels.22, 5.88, and 25.4 ng/ml (.22, 5.88, and 25.4 µg/l). Troponin T measurements were performed with an Elecsys 21 analyzer (Roche, Almere, the Netherlands). For these measurements, the third-generation troponin T reagent was used. This reagent is calibrated with standards of human origin, whereas the second generation uses standards of bovine origin. Furthermore, the third generation uses a 1 amino acid modified signal antibody. These modifications result in a better linearity than that of the second-generation troponin T reagent. 15 Myoglobin was measured using the BNII nephelometer (Dade-Behring, Leusden, the Netherlands) according to the instructions of the manufacturer. HBD activities were measured at 37 C using HBD reagent (product number , Roche-Boehringer Mannheim, Almere, the Netherlands) on a Mega analyzer (Merck, Amsterdam, the Netherlands). For all methods, the linearity was validated by using various dilutions of different tissue homogenate solutions. No blank reaction was observed for any assay methods using the modified phosphate-buffered saline. The protein measurements were performed using the pyrogallol red method (product number A1217, Biotrol Diagnostic, Chennevières les-louvres, France, manufactured by Merck) on a Mega analyzer. The instructions of the manufacturer were modified by using 3 µl of homogenate solution and 25 µl of reagent. This modification resulted in an enhancement of the linearity up to 4 g/l. The imprecision was determined using 2 controls. The mean value of control 1 was.78 g/l (SD.4 g/l), and that of control 2 was 2.98 g/l (SD.11 g/l). The measured concentrations of the tissue homogenate solutions were between 1 and 3 g/l. Biochemical results were expressed as micrograms for both troponin I methods and for troponin T, milligrams for myoglobin, and units for HBD per gram wet weight myocardial tissue and per gram of protein. Statistical Analysis Differences of the biochemical markers among the sampled locations were tested by using the Friedman test. If significant differences were found with the Friedman test, the Wilcoxon signed rank test was used as the post hoc test between the individual sampled locations using the Bonferroni correction method. Differences in heart weight were considered by testing differences in content of biochemical markers for the sampled locations in normal (heart weight, 45 g or less) and hypertrophic (heart weight, more than 45 g) hearts using the Mann-Whitney U test. P values of.5 or less were considered statistically significant. Sex dependency also was considered. American Society of Clinical Pathologists Am J Clin Pathol 21;115:
3 Swaanenburg et al / TROPONINS I AND T, MYOGLOBIN, AND HBD IN THE HUMAN HEART Results The patient characteristics (age, sex, cause of death, heart weight, and interval between the death and autopsy) are given in Table 1. There were 18 women, mean age 62 years (range, years). Their mean heart weight was 365 g (range, g), and the mean interval between death and autopsy was 26 hours (range, 4-48 hours). For the 16 men included in the study, mean age was 66 years (range, years). The mean heart weight was 441 g (range, g), and the mean interval between death and autopsy was 15 hours (range, 6-24 hours). The patients died of a variety of causes: pulmonary disease, 1; (metastatic) cancer, 7; cerebral disease, 5; infectious disease, 4; heart disease, 4; vascular cause, 2; or miscellaneous causes, 2. Table 2 shows the content of the studied biochemical markers in the different parts of the LV. Table 2 shows that within the LV, there was no statistically significant difference between the sampled areas: posterior, lateral, and anterior walls and the interventricular septum. Therefore, mean values of the LV samples will be discussed. Figure 1 gives the ranges of the contents expressed per gram wet weight tissue for the studied biochemical markers per myocardial site and the ranges of the contents of the Table 1 Patient Characteristics Case No./Sex/Age (y) Cause of Death Heart Weight (g) Time Between Death and Autopsy (h) 1/F/86 Heart failure /M/56 Heart failure /M/91 Pneumonia /F/64 Amyloidosis, left ventricular hypertrophy /F/75 Cardiomyopathy /M/6 Intracranial bleeding 4 9 7/M/67 Metastatic lung cancer /M/62 Pulmonary embolism /M/52 Pulmonary embolism /F/52 Metastatic endometrial cancer /F/91 Respiratory insufficiency in interstitial lung disease /F/64 Metastatic endometrial cancer /M/73 Sepsis and multiorgan failure /F/47 Respiratory insufficiency /M/87 Bronchopneumonia, Wegener disease /F/4 Encephalitis /F/56 Meningitis /F/34 Sudden death, right ventricular dysplasia /F/76 Pneumonia 6 1 2/M/54 Metastatic lung cancer /F/29 Metastatic breast cancer /F/68 Pneumonia /M/66 Intracranial bleeding /M/7 Aortic aneurysm /M/6 Pulmonary embolism /M/63 Septic shock /F/49 Metastatic pancreatic cancer /M/61 Pancreatitis /M/59 Pulmonary embolism /F/53 Hemochromatosis /F/71 Abdominal aneurysm /M/74 Pancreatitis, adult respiratory distress syndrome /F/74 Cerebral infection /F/81 Metastatic cancer, unknown primary site Table 2 Content of Various Biochemical Markers at Different Places in the Left Ventricle of the Human Heart * Biochemical Marker Posterior Wall Lateral Wall Anterior Wall Septum Overall Troponin I, Access (µg) 77 (.2-543) 69 (.4-62) 68 (.1-459) 67 (.1-491) 71 (.4-62) Troponin I, AxSYM (µg) 2,72 ( ,52) 2,338 (8.4-22,374) 3,182 (8.6-15,756) 2,787 (6.5-1,678) 2,453 (6.5-22,374) Troponin T (µg) 85 (17-234) 117 (18-213) 94 (24-244) 17 ( ) 95 ( ) Myoglobin (mg) 2.4 ( ) 2.5 ( ) 2.2 ( ) 2.4 ( ) 2.4 ( ) HBD (U) 143 (38-247) 151 (13-27) 138 (62-196) 135 (5-183) 14 (5-27) HBD, alpha-hydroxybutyric acid dehydrogenase. * Data are given as median (range) per gram wet weight myocardial tissue. No statistically significant differences were detected. Access analyzer, Beckman, Mijdrecht, the Netherlands; AxSYM analyzer, Abbott Diagnostic Division, Hoofddorp, the Netherlands. 772 Am J Clin Pathol 21;115: American Society of Clinical Pathologists
4 Clinical Chemistry / ORIGINAL ARTICLE A B 7 25, 6 2, 5 Troponin I 4 3 Troponin I 15, 1, 2 1 5, C D Troponin T 3 2 Myoglobin E HBD Figure 1 The ranges of contents expressed per gram wet weight myocardial tissue for several cardiac markers sampled at different locations in the heart and the ranges of contents per gram wet weight skeletal tissue. A, Troponin I measured by the Access analyzer, Beckman, Mijdrecht, the Netherlands. B, Troponin I measured by the AxSYM analyzer, Abbott Diagnostic Division, Hoofddorp, the Netherlands. C, Troponin T (µg/g wet weight tissue). D, Myoglobin (mg/g wet weight tissue). E, alpha-hydroxybutyric acid dehydrogenase (HBD; U/g wet weight tissue). The contents of the RV and the LV were significantly higher than those of the RA and the LA for all markers (P <.5); for troponin I by the Access analyzer, troponin T, myoglobin, and HBD, the contents of the LV were significantly higher than those of the RV (P <.5). LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle; SM, skeletal muscle. American Society of Clinical Pathologists Am J Clin Pathol 21;115:
5 Swaanenburg et al / TROPONINS I AND T, MYOGLOBIN, AND HBD IN THE HUMAN HEART skeletal muscle tissue. Figure 2 shows these contents per gram of protein. The contents of troponin I by the Access method, troponin T, myoglobin, and HBD per gram wet weight myocardial tissue of the RV were significantly lower (P <.5) than those of the LV overall. In contrast, there was no difference in the contents per gram of protein. Furthermore, the contents per gram wet weight tissue and per gram of protein of all studied markers in the RV and the LV were significantly higher than those in the RA and the LA. The contents of biochemical markers in the RA did not differ significantly (P >.5) from those in the LA. For all sampled sites, we observed lower results with the Access method than with the AxSYM method. The contents of the studied troponins were at least 5 times less in skeletal muscle than in the various sites of the heart. The measured values of the skeletal muscle can be explained by nonspecific binding. This was confirmed by using immunoblot technology: in skeletal muscle tissue homogenate, no cardiac troponin could be demonstrated. The content of HBD in skeletal muscle was 1.5 to 5 times less than in the studied heart sites. The content of myoglobin in skeletal muscle was 1.5 to 4 times higher than in heart muscle tissue. Table 3 gives the median contents per gram wet weight myocardial tissue and per gram of protein for sampled sites (RV, LV overall, RA, and LA) and of the skeletal muscle tissue for both cardiac troponin I methods, cardiac troponin T, myoglobin, and HBD. We observed no heart-weight dependency of contents of the studied biochemical markers in any sampled locations between normal (n = 25) and hypertrophic (n = 9) hearts (all P values >.5). Furthermore, no differences were found in biochemical contents between the hearts of male and female patients (all P values >.5). Discussion We studied the contents of various cardiac markers per gram wet weight tissue and per gram of protein. In addition, we analyzed the distributions of cardiac troponin I, cardiac troponin T, HBD, and myoglobin in the human heart. The person-to-person variety of the contents was high (the contents differed for some persons more than 5 times). Furthermore, the distribution of the markers through the heart was not homogeneous. The biochemical contents in the RA and the LA were significantly lower than those in the RV and the LV, whereas the contents in the RA and the LA did not differ significantly. Furthermore, the contents expressed per gram wet weight tissue in the RV were, in contrast with the contents expressed per gram of protein, significantly lower than those in the LV for troponin I by the Access method, troponin T, myoglobin, and HBD. The contents within the LV showed no differences for all studied biochemical markers in the various LV sites. We also studied sex and heart-weight dependency. Although the mean heart weight of women (365 g) was lower than that of men (441 g), we found no statistically significant differences between the contents of the studied markers in female and male hearts. Furthermore, we found no statistically significant differences between the contents of normal and hypertrophic hearts. In clinical practice, the extent of myocardial tissue injury is based on levels of cardiac markers in serum. However, the nonhomogeneous distribution of cardiac markers in the heart implies the necessity of knowing the site of the damage for determining the loss of myocardial tissue: the atria should be analyzed apart from the ventricles. A consequence of the reported person-to-person variety in tissue contents of cardiac markers is that an individual patient with higher cardiac marker levels in serum after an AMI does not necessarily have more myocardial injury than another patient who has lower cardiac marker levels in the serum at the same time interval after an AMI. In contrast, groups of patients (for example, in clinical trials) could be compared for estimations of myocardial damage using cardiac marker levels in serum, if the following conditions have been fulfilled: similar distributions of baseline characteristics and sufficiently large sample sizes (type B error). The difference between the results of the 2 troponin I measurement methods is related to the nonuniformity of the troponin I analysis, which is, on the one hand, due to lack of consensus about the use of the antibody required to detect troponin I. On the other hand, there is no consensus about the composition of the gold standard for uniform troponin assay calibration. The results of the various troponin I methods will become more comparable if such a gold standard is accepted and introduced by the different assay manufacturers. However, realization of such a standard is complicated, as troponin is present in the circulation in various forms, including free and several complexes such as troponin I troponin C, troponin I troponin C troponin T, and troponin I troponin T. 16 Nevertheless, an American Association for Clinical Chemistry standardization subcommittee is working on this subject and probably will provide guidelines in the near future. 17 The influence of possible changes of the conformation and composition of troponin-bound complexes in the interval between death and autopsy was studied according to the procedure reported by Kragten et al. 9 The intervals between death and autopsy of the studied patients were related to the tissue contents for all studied cardiac markers. We found no significant (negative) correlation between the intervals and any of the studied cardiac markers. From this finding, we conclude that during the interval between death and autopsy, 774 Am J Clin Pathol 21;115: American Society of Clinical Pathologists
6 Clinical Chemistry / ORIGINAL ARTICLE A 2 B Troponin I 1 Troponin I C D Troponin T 5 Myoglobin E HBD Figure 2 The ranges of contents expressed per gram of protein for several cardiac markers sampled at different sites in the heart and the ranges of contents per gram of protein in skeletal muscle are shown. A, Troponin I measured by the Access analyzer. B, Troponin I measured by the AxSYM analyzer. C, Troponin T (µg/g protein). D, Myoglobin (mg/g protein). E, alpha-hydroxybutyric acid dehydrogenase (HBD; U/g protein). For all markers, the contents of the RV and LV were significantly higher than those of the RA and the LA (P <.5); there were no significant differences between the RV and the LV. LA, left atrium (P >.5); For explanation of abbreviations and proprietary information, see the legend for Figure 1. American Society of Clinical Pathologists Am J Clin Pathol 21;115:
7 Swaanenburg et al / TROPONINS I AND T, MYOGLOBIN, AND HBD IN THE HUMAN HEART Table 3 Content of Various Biochemical Markers at Different Places in the Human Heart and in Skeletal Muscle Tissue * Right Ventricle Left Ventricle Right Atrium Left Atrium Skeletal Muscle Biochemical Marker WW Protein WW Protein WW Protein WW Protein WW Protein Troponin I, Access (µg) Troponin I, AxSYM (µg) 2, , , , Troponin T (µg) Myoglobin (mg) HBD (U) HBD, alpha-hydroxybutyric acid dehydrogenase. * Data are given per gram wet weight (WW) of myocardial tissue and per gram of protein. For proprietary information, see Table 2. no significant changes take place in the conformation and composition of the troponin-bound complexes. Although for several years increased concentrations in blood of cardiac markers have been used to estimate the extent of myocardial necrosis, only a few publications address the distribution and content of biochemical parameters in the human heart. van der Laarse et al 1 reported no difference between the enzyme content expressed per gram wet weight tissue in the RV and the LV of tissue obtained by biopsy during open heart surgery. They reported a mean content of 12 U/g wet weight myocardium for HBD. In contrast with our experiments, these HBD measurements were performed at 25 C. Furthermore, these results were based on LV tissue obtained by biopsy from 6 patients and RV tissue obtained by biopsy from 9 patients. It is unclear whether these tissues were derived (partly) from the same patients. In contrast with the results of van der Laarse et al, 1 we observed statistically significant differences among the contents (per gram wet weight tissue) in the RV and the LV. In addition to the previously described discrepancy in the number of patients from whom tissue was harvested from the RV and LV (in our study, n = 34 vs van der Laarse et al, n = 6 [LV] and n = 9 [RV]), the collection procedure was different (autopsy vs biopsy). Finally, we used the Friedman and Wilcoxon signed rank tests to compare the results of the contents in the RV and the LV; van der Laarse et al 1 used a t test to test the significance of differences between means of 2 groups and the Fisher F test to test the significance of differences between variances of 2 groups. Kragten et al 9 reported the content per gram wet weight tissue for HBD and for troponin T from only the LV tissue derived from 17 patients at autopsy. They reported a mean HBD content of 156 U/g wet weight, which is in agreement with our findings. The mean troponin T content was reported as 234 µg/g wet weight. This is more than twice the value we observed. However, Kragten et al 9 used the second-generation troponin T reagent, whereas we used the third-generation reagent. As reported, 15 this third-generation troponin T assay is more accurate, demonstrates improved linearity, and shows lower results beyond values of.2 µg/l compared with the second-generation troponin T assay. Between. and.2 µg/l there is no difference in results between the second- and the third-generation assays. The difference in results starts at a level of.2 µg/l. At a level of 1 µg/l, the results of the third-generation reagent are 5% of those determined by the second-generation reagent. At a level of 25 µg/l, the results with the third-generation reagent are 4% of those with the second-generation reagent. 7 All our measurements in the tissue homogenates were performed in diluted samples because the undiluted tissue-homogenate solutions would be out of the analyzer range. Homogenate solutions were diluted to concentrations between 1 and 15 µg/l. As stated, the difference between the second- and third-generation troponin T reagents is, at this level, a factor between 2 and 2.5. This might be a reasonable explanation for the difference in troponin T contents in our findings and those reported by Kragten et al. 9 Katus et al 11 reported only free troponin T contents in the LVs of hearts from 3 patients undergoing heart transplantation. These patients are different from our population, because most of the patients in our study had no history of heart disease, and none of the patients underwent heart transplantation. Bleier et al 12 reported the content per gram wet weight tissue of myoglobin, troponin I, and troponin T in the RA from 11 patients undergoing heart surgery. They reported a mean myoglobin content of.97 mg/g wet weight, which is in agreement with our findings for the RA. The lack of standardization of the troponin analysis and the use of other troponin I and troponin T methods may explain the different outcomes of the troponin contents. Voss et al 7 reported the content per gram of protein for cardiac troponin T and for myoglobin in the LV and the RV in hearts of 3 healthy and 3 diseased persons. The cardiac troponin T measurements were not performed with the thirdgeneration reagent, so these results cannot be compared with our findings. The mean content of myoglobin of the LV for the healthy persons was 18.4 mg/g and for diseased persons, 776 Am J Clin Pathol 21;115: American Society of Clinical Pathologists
8 Clinical Chemistry / ORIGINAL ARTICLE 49.8 mg/g (overall mean for these persons was 34.1 mg/g). For the RV, these contents were reported as 28.8 and 66.4 mg/g, respectively (overall mean, 47.6 mg/g). We report similar median values of 46.1 mg/g for the LV and 45.1 for the RV. We conclude that there are statistically significant differences among the contents per gram wet weight tissue in the RV and the LV for the biochemical markers troponin I by the Access method, troponin T, myoglobin, and HBD. The biochemical contents per gram wet weight tissue and per gram of protein in the RA and the LA were significantly lower for all studied biochemical markers compared with those in the RV and the LV. There were no statistically significant differences between the biochemical contents in the RA and the LA. Furthermore, within the LV, there was no statistically significant difference in the posterior, lateral, and anterior wall and interventricular septum sites. For clinical practice, these findings imply that for estimation of myocardial damage using cardiac marker levels in serum, it is useful to know the site (atrium or ventricle) of damage in the heart. Furthermore, comparison of myocardial damage among individuals is not reliable using cardiac marker levels in serum because of the variety in ranges of tissue contents. In contrast, comparison among groups of patients (clinical trials) is possible, if the composition of these groups is similar (eg, the same person-to-person variety) and if the group sizes are large enough. From the Departments of 1 Pathology and Laboratory Medicine and 2 Cardiology, University Hospital Groningen, Groningen, the Netherlands. Address reprint requests to Dr Swaanenburg: Sint Jans Gasthuis, Postbus 29, 6 AA Weert, the Netherlands. References 1. Witteveen SAGJ, Hemker HC, Hollaar L, et al. Quantitation of infarct size in man by means of plasma enzyme levels. Br Heart J. 1975;37: Fioretti P, Slavo M, Brower RVV, et al. Prognosis of patients with different peak serum creatine kinase levels after first myocardial infarction. Eur Heart J. 1985;6: van der Laarse A, Hermens WT, Hollaar L, et al. Assessment of myocardial damage in patients with acute myocardial infarction by serial measurement of serum alphahydroxybutyrate dehydrogenase levels. Am Heart J. 1984;17: Bodor GS. Cardiac troponin I: a highly specific biochemical marker for myocardial infarction. J Clin Immunoassay. 1994;17: Wu AH. Cardiac troponin T: biochemical, analytical, and clinical aspects. J Clin Immunoassay. 1994;17: Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: is MB creatine kinase the choice for the 199s? Circulation. 1993;88: Voss EM, Sharkey SW, Gernert AE, et al. Human and canine cardiac troponin T and creatine kinase-mb distribution in normal and diseased myocardium. Arch Pathol Lab Med. 1995;119: Apple FS. Tissue specificity of cardiac troponin I, cardiac troponin T and creatine kinase-mb. Clin Chim Acta. 1999;284: Kragten JA, Hermens WT, VanDieijen-Visser MP. Quantification of cardiac troponin T release into plasma after acute myocardial infarction: only fractional recovery compared with enzymes. Ann Clin Biochem. 1996;33: van der Laarse A, Dijkshoorn NJ, Hollaar L, et al. The (iso)enzyme activities of lactate dehydrogenase, alphahydroxybutyrate dehydrogenase, creatine kinase and aspartate aminotransferase in human myocardial biopsies and autopsies. Clin Chim Acta. 198;14: Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol. 1991;67: Bleier J, Vorderwinkler KP, Falkensammer J, et al. Different intracellular compartmentations of cardiac troponins and myosin heavy chains: a causal connection to their different early release after myocardial damage. Clin Chem. 1998; 44: Apple FS, Maturen AJ, Mullins RE, et al. Multicenter clinical and analytical evaluation of the AxSYM Troponin-I immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem. 1999;45: Christenson RH, Apple FS, Morgan DL, et al. Cardiac troponin I measurement with the ACCESS immunoassay system: analytical and clinical performance characteristics. Clin Chem. 1998;44: Klein G, Baum H, Gurr E, et al. Multicenter evaluation of two new assays for myoglobin and troponin T on the Elecsys 21 and 11 analyzers [abstract]. Clin Chem. 1999;45:A Katrukha AG, Bereznikova AV, Esakova TV, et al. Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clin Chem. 1997;43: Wu AHB, Feng Y, Moore R, et al, for the American Association for Clinical Chemistry Subcommittee on ctni Standardization. Characterization of cardiac troponin subunit release into serum after myocardial infarction and comparison of assays for troponin T and I. Clin Chem. 1998;44: American Society of Clinical Pathologists Am J Clin Pathol 21;115:
EDUCATIONAL COMMENTARY UNDERSTANDING THE BENEFITS AND CHALLENGES OF HIGH- SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS
SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationBIOCHEMICAL EXAMINATION OF ACUTE MYOCARDIAL INFARCTION. Written by Lenka Fialová, translated by Jan Pláteník
BIOCHEMICAL EXAMINATION OF ACUTE MYOCARDIAL INFARCTION 1 Structure of heart muscle Written by Lenka Fialová, translated by Jan Pláteník Heart muscle (myocardium) is a particular form of striated muscle,
More informationBIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS. As. MARUSHCHAK M.I.
BIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS As. MARUSHCHAK M.I. Heart attack symptoms Acute MI Measurement of cardiac enzyme levels Measure cardiac enzyme levels at regular
More informationHigh Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.
High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer
More informationCardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray
Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the acute
More informationErik J. Fransen, MSc, PhD; Jart H. C. Diris, MSc; Jos G. Maessen, MD, PhD; Wim Th. Hermens, PhD; Marja P. van Dieijen-Visser, MD, PhD
Evaluation of New Cardiac Markers for Ruling Out Myocardial Infarction After Coronary Artery Bypass Grafting* Erik J. Fransen, MSc, PhD; Jart H. C. Diris, MSc; Jos G. Maessen, MD, PhD; Wim Th. Hermens,
More informationMyocardial Infarction
Myocardial Infarction MI = heart attack Defined as necrosis of heart muscle resulting from ischemia. A very significant cause of death worldwide. of these deaths, 33% -50% die before they can reach the
More informationAbout OMICS International
About OMICS International OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700
More informationPharmacologyonline 2: (2010) Newsletter Kakadiya and Shah
ROLE OF CREATINE KINASE MB AND LACTATE DEHYDROGENASE IN CARDIAC FUNCTION A REVIEW Jagdish Kakadiya*, Nehal Shah Department of Pharmacology, Dharmaj Degree Pharmacy College, Petlad- Khambhat Road, Dharmaj,
More information7/31/2018. Overview of Next Generation Cardiac Troponin T High Sensitivity. Disclosures. Course Objectives: high sensitive Troponin T assay
Overview of Next Generation Cardiac Troponin T High Sensitivity Arleen Francis Medical & Scientific Liaison Roche Diagnostics 1 Disclosures Arleen Francis is an employee of Roche Diagnostics and a member
More informationBiomarkers of myocardial infarction. Dr. Mamoun Ahram Cardiovascular system, 2013
Biomarkers of myocardial infarction Dr. Mamoun Ahram Cardiovascular system, 2013 References This lecture Hand-outs Acute Myocardial Infarction A rapid development of myocardial necrosis caused by prolonged
More informationThe Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients
The Journal of International Medical Research 2003; 31: 76 83 The Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients S VATANSEVER 1, V AKKAYA
More informationThe Clinical Laboratory Working with Physicians to Improve Patient Care
The Clinical Laboratory Working with Physicians to Improve Patient Care Michael A. Pesce, PhD Professor Emeritus Columbia University Medical Center Department of Pathology and Cell Biology Objectives Troponin
More informationA fter acute myocardial infarction (AMI), a patient s prognosis
2 CARDIOVASCULAR MEDICINE Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size M Licka, R Zimmermann, J Zehelein, T J Dengler, H A Katus, W Kübler...
More informationUse of Biomarkers for Detection of Acute Myocardial Infarction
Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationSupplementary Online Content
Supplementary Online Content Rubini Giménez M, Twerenbold R, Boeddinghaus J, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction.
More informationMarkers. Clinical Chemistry 46: (2000) Enzymes and Protein
Clinical Chemistry 46:6 817 821 (2000) Enzymes and Protein Markers Troponin T and I Assays Show Decreased Concentrations in Heparin Plasma Compared with Serum: Lower Recoveries in Early than in Late Phases
More informationPost Operative Troponin Leak: David Smyth Christchurch New Zealand
Post Operative Troponin Leak: Does It Really Matter? David Smyth Christchurch New Zealand Life Was Simple Once Transmural Infarction Subendocardial Infarction But the Blood Tests Were n t Perfect Creatine
More informationTable. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer.
Table. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer. Commercially available assays - Company/ platform(s)/ assay LoB a LoD b 99 th
More information13. RECOMMENDATIONS ON USE OF BIOCHEMICAL MARKERS IN ACUTE CORONARY SYNDROME: IFCC PROPOSALS
13. RECOMMENDATIONS ON USE OF BIOCHEMICAL MARKERS IN ACUTE CORONARY SYNDROME: IFCC PROPOSALS Prof. Mauro Panteghini, MD, Ph.D. Chairman of the IFCC Committee on Standardization of Markers of Cardiac Damage
More informationA New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory
e-issn 1643-3750 DOI: 10.12659/MSM.892033 Received: 2014.07.18 Accepted: 2014.08.14 Published: 2015.01.28 A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get
More information1) Severe, crushing substernal chest pain 2) radiate to the neck, jaw, epigastrium, or left arm. 3- rapid and weak pulse 4- nausea (posterior MI).
1) Severe, crushing substernal chest pain 2) radiate to the neck, jaw, epigastrium, or left arm. 3- rapid and weak pulse 4- nausea (posterior MI). 5- cardiogenic shock (massive MIs >40% of the left ventricle)
More informationImpact of Troponin Performance on Patient Care
Impact of Troponin Performance on Patient Care Linda C, Rogers PhD, DABCC, FACB Agenda Introduction Diagnosis of MI Guidelines Troponin Assay differences Classification of troponin assays Guideline acceptable
More informationChallenging Issues in Cardiac Biomarker interpretation. F. Nikaeen. MD interventional Cardiologist
Challenging Issues in Cardiac Biomarker interpretation F. Nikaeen. MD interventional Cardiologist Biomarkers Types of Troponin Troponin C Binds calcium Troponin I Binds actin Troponin T Binds tropomyosin
More informationUniversity of Groningen
University of Groningen The biochemical and clinical assessment of cardiac markers for the detection of various forms of myocardial tissue damage Swaanenburg, Jozef Cornelis Jacobus Maria IMPORTANT NOTE:
More informationCT for Myocardial Characterization of Cardiomyopathy. Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea
CT for Myocardial Characterization of Cardiomyopathy Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea Cardiomyopathy Elliott P et al. Eur Heart J 2008;29:270-276 The European Society
More informationComparison of M yoglobin, Creatine Kinase-MB, and Cardiac Troponin I for Diagnosis of Acute Myocardial Infarction*
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 26, No. 4 Copyright 1996, Institute for Clinical Science, Inc. Comparison of M yoglobin, Creatine Kinase-MB, and Cardiac Troponin I for Diagnosis of Acute
More informationEvaluation of a Rapid Whole Blood ELISA for Quantification of Troponin I in Patients with Acute Chest Pain
Clinical Chemistry 45:10 1789 1796 (1999) Enzymes and Protein Markers Evaluation of a Rapid Whole Blood ELISA for Quantification of Troponin I in Patients with Acute Chest Pain Christopher Heeschen, 1*
More information9/18/2017. Disclosures. Cardiac Troponin: ER Utilization and the Next Generation
Disclosures Cardiac Troponin: ER Utilization and the Next Generation Joshua Soldo is an employee of Roche Diagnostics within the division of Medical Scientific Affairs. Data presented is intended for purely
More informationP1: OTE/SPH P2: OTE BLUK084-Adams April 13, :13 PART 1. Cardiac troponins
PART 1 Cardiac troponins 1 2 CHAPTER 1 Basics of cardiac troponin: practical aspects of assays, potential analytical confounders, and clinical interpretation Fred S. Apple Case 1 Following an episode of
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationUPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18
UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 INTRODUCTION The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment
More informationGUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT
GUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT sponsored by TROPONIN OVERVIEW TROPONIN DETECTION IN NORMAL AND DISEASE STATES1 The detection of
More informationPapers in Press. Published March 23, 2007 as doi: /clinchem
Papers in Press. Published March 23, 2007 as doi:10.1373/clinchem.2006.084715 The latest version is at http://www.clinchem.org/cgi/doi/10.1373/clinchem.2006.084715 Clinical Chemistry 53:4 547 551 (2007)
More informationDefining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationSpeaker: Richard Heitsman, MICT, C-POC-AACC. Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America.
Speaker: Richard Heitsman, MICT, C-POC-AACC Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America. Upon completion the participant will be able to o Review current and evolving
More informationACUTE MYOCARDIAL INFARCTION: DEFINITION, DIAGNOSIS, AND THE EVOLUTION OF CARDIAC MARKERS
ACUTE MYOCARDIAL INFARCTION: DEFINITION, DIAGNOSIS, AND THE EVOLUTION OF CARDIAC MARKERS d Copyright 2018 by. LEARNING OBJECTIVES: 1. Define MI and the challenges in MI diagnosis 2. Define the current
More informationProduct Information. Instruction for Use. Troponin I ELISA kit Catalog Number: EA Storage Temperature: 2 8 C
9620 Medical Center Dr., Suite 200, Rockville, MD 20850 Phone: 1.888.267.4436 Fax: 301-340-9254 Email: techsupport@origene.com Web: www.origene.com Product Information Troponin I ELISA kit Catalog Number:
More informationCost-Effective Utilization of CK-MB Mass and Activity Assays
CHEMISTRY Lokinendi V. Rao, PhD, SC(ASCP) John R. Petersen, PhD, DABCC Amin A. Mohammad, PhD, DABCC Michael G. Bissell, MD, PhD, MPH Anthony. Okorodudu, PhD, MS(MCS), DABCC Cost-Effective Utilization of
More informationHuman Troponin I ELISA Kit
Human Troponin I ELISA Kit Cat. No.:DEIA2358 Pkg.Size:96T Intended use This kit is intended for the quantitative determination of cardiac troponin I in human serum. Measurement of troponin I values are
More informationMultiple studies are available concerning the use of
SPECIAL ARTICLE Evaluation of the Biosite Ò Quantitative Whole Blood D-dimer Assay and Comparison With the biomérieux VIDAS Ò D-dimer Exclusion Test Validation and Utility For Use in the Central Laboratory
More informationTroponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg
Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology
More informationCardiac Troponin I and T Alterations in Dog Hearts With Myocardial Infarction Correlation With Infarct Size
Cardiac Troponin I and T Alterations in Dog Hearts With Myocardial Infarction Correlation With Infarct Size Vincent Ricchiuti, and FredS. Apple, PhD, Scott W. Sharkey, MD, Mary Ann M. Murakami, Ellen M.
More informationDoes serial troponin measurement help identify acute ischemia/ischemic events?
Does serial troponin measurement help identify acute ischemia/ischemic events? Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine and Laboratory Medicine & Pathology
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationhs-c Tn I high sensitivity troponin I <17 min
hs-c Tn I high sensitivity troponin I IFCC & ESC compliant 0/ h NSTEMI rule-out / rule-in algorithm POCT whole blood/plasma Results in < 7 minutes
More informationJournal of the American College of Cardiology Vol. 33, No. 6, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00061-3 for Prediction
More informationClinical Policy: Cardiac Biomarker Testing for Acute Myocardial Infarction Reference Number: CP.MP.156
Clinical Policy: Reference Number: CP.MP.156 Effective Date: 12/17 Last Review Date: 12/17 See Important Reminder at the end of this policy for important regulatory and legal information. Description The
More informationAn Analysis of the Creatine Kinase Isoenzyme and Cardiac Troponin T Levels in a Polymyositis Patient
American Journal of Immunology 4 (1): 1-7, 2008 ISSN 1553-619X 2008 Science Publications An Analysis of the Creatine Kinase Isoenzyme and Cardiac Troponin T Levels in a Polymyositis Patient 1 R.M. Golding,
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationAnalytical performance of the i-stat cardiac troponin I assay
Clinica Chimica Acta 345 (2004) 123 127 www.elsevier.com/locate/clinchim Analytical performance of the i-stat cardiac troponin I assay Fred S. Apple a, *, MaryAnn M. Murakami a, Robert H. Christenson b,
More informationQuantitative measurement of 6 analytes in parallel
Quantitative measurement of 6 analytes in parallel Trop I sensitive, NTproBNP, D-Dimer, hscrp, Myoglobin, HCG, CK-MB mass NEXT GENERATION PATHFAST TM emergency & CRITICAL CARE» 6 samples in parallel» in
More informationComparison of ARCHITECT chemiluminiscent microparticle immunoassay for determination of Troponin I in serum with AXYM MEIA technology
Journal of Health Sciences www.jhsci.ba Volume 1, Number 3, December 2011 Comparison of ARCHITECT chemiluminiscent microparticle immunoassay for determination of Troponin I in serum with AXYM MEIA technology
More informationCREATINE KINASE MB/ (CK-MB)
CREATINE KINASE MB/ (CK-MB) Intended Use The i-stat CK-MB test is an in vitro diagnostic test for the quantitative measurement of creatine kinase MB mass in whole blood or plasma samples. CK-MB measurements
More informationLab 16. The Cardiovascular System Heart and Blood Vessels. Laboratory Objectives
Lab 16 The Cardiovascular System Heart and Blood Vessels Laboratory Objectives Describe the anatomical structures of the heart to include the pericardium, chambers, valves, and major vessels. Describe
More informationCardiac Sarcoidosis. Millee Singh DO Non Invasive Cardiology First Coast Heart and Vascluar
Cardiac Sarcoidosis Millee Singh DO Non Invasive Cardiology First Coast Heart and Vascluar Introduction Multisystem granulomatous disease of unknown etiology characterized by noncaseating granulomas in
More informationEffect of the Inhibition of Mitochondrial Creatine Kinase Activity on the Clinical Diagnosis of Suspected Acute Myocardial Infarction
The Open Clinical Chemistry Journal, 2012, 5, 1-6 1 Open Access Effect of the Inhibition of Mitochondrial Creatine Kinase Activity on the Clinical Diagnosis of Suspected Acute Myocardial Infarction Masato
More informationMultiparametric assessment of the effects of chemotherapeutic drugs on the (electro)physiology of Pluricyte Cardiomyocytes
Multiparametric assessment of the effects of chemotherapeutic drugs on the (electro)physiology of Pluricyte Cardiomyocytes Event Presenter Date Ncardia Workshop Tessa de Korte, MSc December 1, 2017 Page
More informationGamma-Glutamyl Transpeptidase and Other Liver Function Tests in Myocardial Infarction and Heart Failure
Gamma-Glutamyl Transpeptidase and Other Liver Function Tests in Myocardial Infarction and Heart Failure M. G. BETRO, M.B., CH.B., F.R.C.P.A., R. C. S. OON, B.SC, AND J. B. EDWARDS, PH.D. Division of Clinical
More information10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better
10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department
More informationUtility of Heart-Type Fatty Acid Binding Protein in Early Diagnosis of Acute Coronary Syndrome
Med. J. Cairo Univ., Vol. 84, No. 1, March: 2 7-33, 2016 www.medicaljournalofcairouniversity.net Utility of Heart-Type Fatty Acid Binding Protein in Early Diagnosis of Acute Coronary Syndrome MOHAMED HASAN,
More informationAnalysis of formaldehyde in blood of rats during and after inhalation exposure
Analysis of formaldehyde in blood of rats during and after inhalation exposure Sponsor: Research laboratory: P.O. Box 844 3700 AV Zeist The Netherlands Presenter: Dr. A.J. Kleinnijenhuis T +31 88 866 28
More informationProcedures: LifeSign MI Myoglobin/CK-MB/Troponin I Test. Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature
Procedures: LifeSign MI Myoglobin/CK-MB/Troponin I Test Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature Distributed to # of Copies Distributed to # of Copies PRINCIPLE:
More informationRestrictive Cardiomyopathy
ESC Congress 2011, Paris Imaging Unusual Causes of Cardiomyopathy Restrictive Cardiomyopathy Kazuaki Tanabe, MD, PhD Professor of Medicine Chair, Division of Cardiology Izumo, Japan I Have No Disclosures
More informationInternationally indexed journal
www.ijpbs.net Internationally indexed journal Indexed in Chemical Abstract Services (USA), Index coppernicus, Ulrichs Directory of Periodicals, Google scholar, CABI,DOAJ, PSOAR, EBSCO, Open J gate, Proquest,
More informationOriginal Article ABSTRACT. Kiumars Ahmadi 1 PhD, Fahimeh Dadgari 1 MS, Mohammad Reza Safarinejad 2 MD
Original Article The most sensitive double-marker method of cardiac isoenzymes of creatinine kinase, troponin I, and myoglobin in different time periods for diagnosing acute myocardial infarction Kiumars
More informationT he World Health Organization defined myocardial infarction
343 CARDIOVASCULAR MEDICINE Myocardial infarction redefined: the new ACC/ESC definition, based on cardiac troponin, increases the apparent incidence of infarction J L Ferguson, G J Beckett, M Stoddart,
More informationCV Anatomy Quiz. Dr Ella Kim Dr Pip Green
CV Anatomy Quiz Dr Ella Kim Dr Pip Green Q1 The location of the heart is correctly described as A) lateral to the lungs. B) medial to the sternum. C) superior to the diaphragm. D) posterior to the spinal
More informationSang Ling Wu, MD, Wei Li, MD, PhD, Alice Wells, MT(ASCP), and Amitava Dasgupta, PhD
Clinical Chemistry / DIGOXIN-LIKE AND DIGITOXIN-LIKE IMMUNOREACTIVE SUBSTANCES IN ELDERLY PEOPLE Digoxin-Like and Digitoxin-Like Immunoreactive Substances in Elderly People Impact on Therapeutic Drug Monitoring
More informationPeri-operative Troponin Measurements - Pathophysiology and Prognosis
Peri-operative Troponin Measurements - Pathophysiology and Prognosis Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationMario Plebani University-Hospital of Padova, Italy
Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO
More informationWaiting for High-Sensitivity POCT Cardiac Troponin Assays: Clinical and Analytical Needs I Have a Pain in My Chest That Hurts Very Bad
Waiting for High-Sensitivity POCT Cardiac Troponin Assays: Clinical and Analytical Needs I Have a Pain in My Chest That Hurts Very Bad Fred Apple PhD Hennepin County Medical Center University of Minnesota
More informationCardiac troponin (ctn) testing is an
CLINICIAN UPDATE How to Interpret Elevated Cardiac Troponin Levels Vinay S. Mahajan, MD, PhD; Petr Jarolim, MD, PhD Cardiac troponin (ctn) testing is an essential component of the diagnostic workup and
More informationAnalytical Characteristics of High-Sensitivity Cardiac Troponin Assays
Clinical Chemistry 58:1 54 61 (2012) Mini-Reviews Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays Fred S. Apple 1,2* and Paul O. Collinson, 3 for the IFCC Task Force on Clinical
More informationTroponin-I (ctni) and troponin-t (ctnt) are wellestablished
Comparison of and After Pediatric Cardiovascular Operation Franz F. Immer, MD, Franco P. Stocker, MD, Andrea M. Seiler, MD, Jean-Pierre Pfammatter, MD, Gerhardt Printzen, MD, and Thierry P. Carrel, MD
More informationTroponin I Measurement: Evolution of a Biomarker Essential for Assessment of Myocardial Injury
Troponin I Measurement: Evolution of a Biomarker Essential for Assessment of Myocardial Injury Robert H. Christenson, Ph.D., DABCC, FACB Professor of Pathology Professor of Medical and Research Technology
More informationConcurrent Subarachnoid Hemorrhage and Acute Myocardial Infarction: A Case Report
Concurrent subarachnoid hemorrhage and AMI 155 Concurrent Subarachnoid Hemorrhage and Acute Myocardial Infarction: A Case Report Chen-Chuan Cheng 1, Wen-Shiann Wu 1, Chun-Yen Chiang 1, Tsuei-Yuang Huang
More informationOriginal Research Article
ASSESSMENT OF LEFT VENTRICULAR FUNCTION USING 12-LEAD ECG AND CARDIAC TROPONIN-T IN CORRELATION WITH 2D-ECHO FOLLOWING NEW-ONSET MYOCARDIAL INFARCTION Peddi Bhaskar 1, Bikshapathi Rao 2, Naveen 3 1Associate
More informationNews. Laboratory. CHANGES IN CARDIAC TROPONIN I REPORTING Gene Shaw, MD, Annu Khajuria, PhD. Inside This Issue
Laboratory News Inside This Issue CHANGES IN CARDIAC TROPONIN I REPORTING...1 FOUR NEW SEROLOGY TESTS FOR AUTOIMMUNE LIVER DISEASES...3 INSULIN LIKE GROWTH FACTOR-1 (IGF-1) METHOD CHANGES...6 CHANGES IN
More informationJMSCR Vol 05 Issue 01 Page January 2017
JMSCR Vol Issue Page 93-943 January 27 www.jmscr.igmpublication.org Impact Factor.84 Index Copernicus Value: 83.27 ISSN (e)-2347-76x ISSN (p) 24-4 DOI: https://dx.doi.org/.83/jmscr/vi.3 Elevation of Troponin-I
More informationThe Heart. Happy Friday! #takeoutyournotes #testnotgradedyet
The Heart Happy Friday! #takeoutyournotes #testnotgradedyet Introduction Cardiovascular system distributes blood Pump (heart) Distribution areas (capillaries) Heart has 4 compartments 2 receive blood (atria)
More informationRECOMMENDATIONS FOR USE OF POINT-OF- CARE TROPONIN ASSAYS IN ASSESSMENT OF ACUTE CORONARY SYNDROME
RECOMMENDATIONS FOR USE OF POINT-OF- CARE TROPONIN ASSAYS IN ASSESSMENT OF ACUTE CORONARY SYNDROME Dr Philip Tideman on behalf of Troponin Working Party Troponin PoCT Working Party Louise Cullen (ACEM)
More informationtroponin I T CK - MB
: 58 2 2000 troponin I T CK - MB, * * * = A bs tra c t= T ni, ct nt, and CK- MB in patients w ith chronic renal f ailure Jung E Yun, M.D., Hyung Cheol Lee, M.D., June Sang Lee, M.D. Kyu Yong Park, M.D.,
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationCh.15 Cardiovascular System Pgs {15-12} {15-13}
Ch.15 Cardiovascular System Pgs {15-12} {15-13} E. Skeleton of the Heart 1. The skeleton of the heart is composed of rings of dense connective tissue and other masses of connective tissue in the interventricular
More informationDr. Dermot Phelan MB BCh BAO PhD European Society of Cardiology 2012
Relative Apical Sparing of Longitudinal Strain Using 2- Dimensional Speckle-Tracking Echocardiography is Both Sensitive and Specific for the Diagnosis of Cardiac Amyloidosis. Dr. Dermot Phelan MB BCh BAO
More informationTiming of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism
7 Frederikus A. Klok Noortje van der Bijl Inge C.M. Mos Albert de Roos Lucia J. M. Kroft Menno V. Huisman Timing of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism Letter
More informationExercise in Adverse Cardiac Remodeling: of Mice and Men
Exercise in Adverse Cardiac Remodeling: of Mice and Men 17-01-2013 Dirk J Duncker Experimental Cardiology, Cardiology, Thoraxcenter Cardiovascular Research Institute COEUR Erasmus MC, University Medical
More informationWhat can we learn from EQAs and audits for cardiac marker testing?
What can we learn from EQAs and audits for cardiac marker testing? Dr P. O. Collinson MA MB BChir FRCPath MD FACB Consultant Chemical Pathologist and Director of Clinical Blood Sciences, Head of Vascular
More informationLec: 21 Biochemistry Dr. Anwar J Almzaiel. Clinical enzymology. Very efficient can increase reaction rates at the order of x 10
Clinical enzymology Enzymes Biological catalysis Very efficient can increase reaction rates at the order of x 10 All are proteins- so liable to denaturation Specific to substrates Partly specific to tissues
More informationTROPONINS HAVE THEY CHANGED YOUR
TROPONINS HAVE THEY CHANGED YOUR PRACTICE THIS WEEK? Harvey White John Neutze Scholar Green Lane Cardiovascular Service and Cardiovascular Research Unit Auckland City Hospital, Auckland, New Zealand Disclosure
More informationPerioperative myocardial cell injury: the role of troponins
British Journal of Anaesthesia 1997; 78: 386 390 Perioperative myocardial cell injury: the role of troponins H. METZLER, M. GRIES, P. REHAK, TH. LANG, S. FRUHWALD AND W. TOLLER Summary Early recognition
More informationClinical Cardiology Frontiers
750 Clinical Cardiology Frontiers Biochemical Markers of Myocardial Injury Is MB Creatine Kinase the Choice for the 1990s? Jesse E. Adams III, MD; Dana R. Abendschein, PhD; Allan S. Jaffe, MD M odern medical
More informationThe Universal Definition of Myocardial Infarction 3 rd revision, 2012
The Universal Definition of Myocardial Infarction 3 rd revision, 2012 Joseph S. Alpert, MD Professor of Medicine, University of Arizona College of Medicine, Tucson, AZ; Editor-in-Chief, American Journal
More informationTroponin: leaks, bumps and elevations : is it an MI or. question?.
Troponin: leaks, bumps and elevations : is it an MI or not an MI that is the question?. John E. Ellis MD Adjunct Professor University of Pennsylvania Anesthesiology and Critical Care www.vascularanesthesia.com
More informationSingle-Point Cardiac Troponin T at Coronary Care Unit Discharge after Myocardial Infarction Correlates with Infarct Size and Ejection Fraction
Clinical Chemistry 48:9 1432 1436 (2002) Enzymes and Protein Markers Single-Point Cardiac Troponin T at Coronary Care Unit Discharge after Myocardial Infarction Correlates with Infarct Size and Ejection
More informationIschemic heart disease
Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery
More informationClassification of lab tests useful in cardiac disease Biochemical markers in Acute Coronary Syndromes (ACS) Redefinition of Myocardial Infarction (MI)
Biochemical Markers in Cardiac Injury Dr Sami Saeed Assistant Professor/Consultant Chemical Pathologist Foundation University Medical College Fauji Foundation Hospital Rawalpindi Email: drsami@comsats.net.pk
More informationQuantitative measurement of 6 analytes in parallel hs Trop I, NTproBNP, D-Dimer, hscrp, Myoglobin, HCG, CK-MB mass
Quantitative measurement of 6 analytes in parallel hs Trop I, NTproBNP, D-Dimer, hscrp, Myoglobin, HCG, CK-MB mass High Sensitivity NEW MARKER Tr o p o n in I EMERGENCY & CRITICAL CARE» 6 samples in parallel»
More information